Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lecavin is a three-chamber bag (3CB) parenteral nutrition formulation developed by Huarui Pharmaceutical (a Fresenius Kabi joint venture) for the Chinese market. It contains a structured lipid emulsion, amino acids, and glucose in separate compartments that are mixed immediately prior to intravenous infusion. The structured lipid component is a randomized triglyceride mixture of long-chain (LCT) and medium-chain (MCT) fatty acids, designed to provide a balanced energy source with improved metabolic clearance compared to traditional LCT emulsions. Lecavin is intended for total parenteral nutrition in adult patients, particularly those recovering from moderate to major abdominal surgery, to support protein synthesis, maintain nitrogen balance, and provide essential energy when enteral nutrition is inadequate or contraindicated.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on structured lipid emulsion + amino acids + glucose.